149 results about "Gastrointestinal cancer" patented technology

The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The invention belongs to the technical field of medical image intelligent processing, in particular to a gastrointestinal endoscopic image classification and early cancer detection system based on a multi-task neural network. The system of the invention comprises: (1) a feature extraction backbone network; (2) Classification of gastrointestinal endoscopic images; (3) regional detection branch of early gastrointestinal cancer. The invention adopts a multi-task depth neural network structure, and classifies and detects two tasks to share a plurality of convolution layers. Endoscopic images are inputted into the neural network model, and the detection and classification results can be obtained simultaneously after a forward propagation, which can effectively reduce the computational load andimprove the classification and detection accuracy. The experimental results show that the invention can accurately classify the endoscopic images into normal and early cancers and detect the irregularlesion areas in the early cancers images, reduce the influence of human factors and improve the efficiency of clinical diagnosis.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

This invention relates to methods and compositions for determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as gastric or colorectal cancer, based on cell proliferation signatures. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a personalized genomics profile for a cancer patient, among other methods as well as kits and devices for carrying out these methods.

A method of treating gastrointestinal cancers dependent on the prohormones amidated gastrin-17 and glycine extended G-17, comprising the administration to the patient of an anti-gastrin 17 immunogen which induces antibodies which bind and neutralize amidated and glycine-extended gastrin-17.

A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.

An endoscopic cryoablation apparatus for the ablation of unwanted tissues is disclosed. A method of utilizing the apparatus for ablating pancreatic cancer, gastrointestinal cancers, or other undesired tissue is also incorporated. The apparatus provides a cryoprobe needle tip covered by an outer sheath at a distal end of a catheter shaft such that the distal end includes a defined ablation zone. As implemented, the cryocatheter can be utilized alone or in combination with and endoscopic ultrasound. A moveable handle attached to the outer sheath is configured such that the handle retracts and protracts the outer sheath to expose and cover, respectively, the cryoprobe needle tip.

A method of evaluating gastrointestinal cancer risk. The method comprises generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual, providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals, and evaluating, using a processor, a gastrointestinal cancer risk of the target individual by classifying the set of features using the at least one classifier.

Methods and kits for diagnosing cancer or a pre-malignant lesion by determining the presence and / or level of circulating CD24 of a subject are provided. Also provided are methods and kits for determining if a subject is predisposed to gastrointestinal cancer by the determining the presence or absence, in a homozygous or heterozygous form of cancer associated genotype(s) in the CD24 and / or APC nucleic acid sequences. Also provided are methods and kits for monitoring efficacy of cancer therapy by determining the presence and / or level of circulating CD24 of a subject.

The invention relates to a composition comprising cannabidiol and Denbinobin and its use in medicine, for example, for the prevention and treatment of gastrointestinal inflammatory diseases and for the prevention and treatment of gastrointestinal cancers.

The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

The invention provides a noninvasive examination device for gastrointestinal precancerous lesions. The noninvasive examination device comprises a gastrointestinal intracavity white light / fluorescence image acquisition and wireless transmission micro-robot examination subsystem, a lying-in-bed driving subsystem, a human-computer interface control subsystem and a wireless energy supply subsystem. Through a wireless energy supply and active control system, the noninvasive examination device can be controllable in a gastrointestinal tract of a testee and can be used for examination for a long time, examination results can be sent outside the body of the testee in a wireless mode, and consequently noninvasive and painless examination of the whole digestive tract can be achieved.

The present invention discloses soybean oligosacchairde health bent and its preparation process, and aims at providing one kind of health beer. Before the package of beer, certain amount of soybean oligosaccharide is added into beer through stirring for 1-5 min to make each 100 ml beer of beer product contains soybean oligosacchairde in 0.4-5 g. The present invention has the health functions of promoting the proliferation of bifidobacterium, relaxing and bowels, lowering serum cholesterol, protecting liver, resisting senility and preventing and treating gastrointestinal cancer.

This invention provides information on differentially expressed genes in malignant tissue of gastric, colon and pancreatic adenocarcinomas as compared to their corresponding adjacent non-malignant tissues. These genes or their products can be used as targets in developing new strategies for the treatment and diagnosis of these gastrointestinal cancers.

Methods for the treatment of cancers involving dysregulation of thromboxane receptor β (TP-β) are provided, including in certain aspects methods for diagnosing such cancers. Specific cancers included are genitourinary cancers, gastrointestinal cancers and leukemias.

A freeze-dried hydroxy camptothecin powder injection for treating primary liver cancer, gastrointestinal cancer, vesical cancer, lung cancer, leukemia, etc is prepared from hydroxy camptothecin, aminoacetic acid, lactose, sodium hydroxide and the water for injection through preparing buffer liquid from sodium hydroxide, aminoacetic acid and the water for injection, dissolving hydroxy camptothecinin it to obtain solution A, dissolving lactose in the water for injection to obtain solution B, adding A and rest of aminoacetic acid to B, stirring, regulating pH value, adding water for injection, filtering loading in containers, freeze drying and sealing.

The invention relates to a nutrient return rice noodle, which is characterized by taking rice and rice bran as raw materials. Rice bran is added in the process of making rice noodles from rice so as to reach a nutrient return effect. The nutrition of the rice noodle can be increased, the taste of the rice noodle is improved, and the rice noodle can have a plurality of health care and recuperation functions. The added rice bran serves as a nutritional supplement, and plays a role of balancing nutrition and improving absorption. A mixture of rice and rice bran can well preserve the nutritional substances of rough rice, and helps to reduce the risks of heart disease, gastrointestinal cancer and diabetes, prevent puffiness and enhance resistance. The making method of the product provided by the invention is similar to conventional rice noodle making methods. The nutrient return rice noodle provided by the invention can be made into dry rice noodle, and also can be made into wet rice noodle.

The invention provides novel formulations of guanylate cyclase-C(“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

The invention discloses a culture medium of hericium erinaceus, a bio-converted mycelium, an extract of the bio-converted mycelium, and an application of the extract. The culture medium is prepared by adding a traditional Chinese medicine, sculellaria barbata, to a base culture medium and includes the base culture medium and the sculellaria barbata. 100 parts of the culture medium includes 50-70 parts of the base culture medium and 30-50 parts of the sculellaria barbata, wherein the base culture medium includes, by weight, 350-490 parts of wheat bran, 100-140 parts of corn flour, 45-63 parts of grain bran, 5-7 parts of white sugar and 400-600 parts of water. The bio-converted mycelium is a product that is prepared by inoculating the hericium erinaceus on the culture medium through mycelium conversion. The extract of the bio-converted mycelium is prepared by water-extracting and then pressure-reduced-concentrating the hericium erinaceus mycelium and finally performing vacuum freeze-drying. The extract of the bio-converted mycelium has the effect of resisting gastrointestinal cancer, wherein the effect is significantly better than that of the hericium erinaceus mycelium and the sculellaria barbata independently, so that the extract can be used for preparing an anti-gastrointestinal cancer medicine.

The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating gastointestinal cancers including small intestine, colon and stomach cancer.

The present invention is for composition containing extract of Northern White Kidney Bean (Phaseolus vulgaris), extract of Red Kidney Bean (Locust Bean Gum) (Ceratonia siliqua) and extract of Green Tea (Camellia Sinensis). This invention as a supplemental compound, aids in weight reduction both in overweight and obese individuals. This invention helps normal weight subjects in improving their quality of life by maintaining their normal weight. Included is also folic acid, (B6) and B12 and the whole supplement is bound by a vegetable matrix. The present invention is directed to methods for inducing weight loss by inhibit the absorption of dietary lipids and starch, increase the metabolic rate and decrease the amino acid homocysteine in the blood, an amino acid known to cause risk of heart disease, by administering a composition of the invention. Due to the content of the green tea extract this invention is also meant to reduce and prevent occurrence of gastrointestinal cancer and cancer of the prostate.

Disclosed are compositions and methods for detecting oral and gastrointestinal cancers in a subject. Autoantigen p90 was shown to be overexpressed in oral cancer cells, and this protein, as well as its companion autoantigen p62 and antibodies directed to both proteins, can be used as markers for detecting oral digestive and other cancers in a subject at an early stage.